Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 12
Submit an article Journal homepage
1,066
Views
28
CrossRef citations to date
0
Altmetric
Original Article: Clinical

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

Jan de JongJanssen Research & Development, San Diego, CA, USA; Correspondence[email protected]
View further author information
,
Peter HellemansJanssen Research & Development, Beerse, Belgium; View further author information
,
Severijn De WildeJanssen Research & Development, Beerse, Belgium; View further author information
,
Daniel PatriciaJanssen Research & Development, Spring House, PA, USA; View further author information
,
Tara MastersonJanssen Research & Development, Spring House, PA, USA; View further author information
,
Georgii ManikhasSt. Petersburg City Oncology Hospital, St. Petersburg, Russian Federation; View further author information
,
Alexander MyasnikovBaranov Republican Hospital, Petrozavodsk, Russian Federation; View further author information
,
Dzhelil OsmanovN.N. Blokhin Russian Academy of Medical Sciences, Moscow, Russian Federation; View further author information
,
Raúl CórdobaSTART Madrid, University Hospital Fundacion Jimenez Diaz, Health Research Institute IIS-FJD, Madrid, Spain; View further author information
,
Carlos PanizoUniversity Clinic of Navarra, Pamplona, Spain; View further author information
,
Loeckie de ZwartJanssen Research & Development, Beerse, Belgium; View further author information
,
Jan SnoeysJanssen Research & Development, Beerse, Belgium; View further author information
,
Vijay ChauhanJanssen Research & Development, Raritan, NJ, USA; View further author information
,
James JiaoJanssen Research & Development, Raritan, NJ, USA; View further author information
,
Juthamas SukbuntherngPharmacyclics LLC, Sunnyvale, CA, USAView further author information
&
Daniele OuelletJanssen Research & Development, Spring House, PA, USA; View further author information
 show all
Pages 2888-2895 | Received 22 Dec 2017, Accepted 25 Mar 2018, Published online: 30 May 2018

Citations (28)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Doreen G. Te Raa, Lina van der Straten, Michel van Gelder, Sabina Kersting, Mark-David Levin, Rogier Mous, Hanneke M. van der Straaten, Marten R. Nijziel, Ellen van der Spek, Eduardus F. M Posthuma, Hein P.J Visser, Marjolein van der Klift, Koen de Heer, Mar Bellido, Jeanette K. Doorduijn, Anke H.W Bruns, Reinier A. P Raijmakers & Arnon P. Kater. (2022) Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. Leukemia & Lymphoma 63:10, pages 2276-2289.
Read now
Hee Jeong Cho, Dong Won Baek, Juhyung Kim, Jung Min Lee, Joon Ho Moon & Sang Kyun Sohn. (2021) Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. Expert Review of Hematology 14:9, pages 819-830.
Read now
Benjamin W. Teh, William Chui, Sasanka Handunnetti, Constantine Tam, Leon J. Worth, Karin A. Thursky & Monica A. Slavin. (2019) High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 60:6, pages 1572-1575.
Read now

Articles from other publishers (25)

Aleksi M. Olkkola, Tuija Tapaninen, Aleksi Tornio, Milka Hauta‐aho, Outi Lapatto‐Reiniluoto, Mikko Neuvonen, Johanna I. Kiiski, Pertti J. Neuvonen, Mikko Niemi & Janne T. Backman. (2023) Posaconazole‐ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatment. British Journal of Clinical Pharmacology.
Crossref
Chao Li, Lu Chen, Lixian Li & Wanyi Chen. (2023) Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir/ritonavir (paxlovid) based on physiologically-based pharmacokinetic models. European Journal of Pharmaceutical Sciences 189, pages 106564.
Crossref
Fernando De la Garza‐Salazar, Perla Rocío Colunga‐Pedraza & David Gómez‐Almaguer. (2022) Cytochrome P450 inhibition to decrease dosage and costs of venetoclax and ibrutinib: A proof‐of‐concept case study. British Journal of Clinical Pharmacology 89:2, pages 898-902.
Crossref
J Maertens, L Pagano, E Azoulay & A Warris. (2022) Liposomal amphotericin B—the present. Journal of Antimicrobial Chemotherapy 77:Supplement_2, pages ii11-ii20.
Crossref
Taylor M Weis, Jillian Gutierrez, Charlene C Kabel, Amber C King, Ryan J Daley & Sarah E Stump. (2022) Real-world management of targeted therapies in chronic lymphocytic leukemia. Journal of Oncology Pharmacy Practice 28:6, pages 1411-1433.
Crossref
Praful Pandey, Ahitagni Biswas, Saphalta Baghmar, Mukesh Patekar & Ranjit Kumar Sahoo. 2022. Lymphoma. Lymphoma.
Tristan M. Sissung & William D. Figg. (2022) Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted. Cancers 14:5, pages 1131.
Crossref
Benjamin KablyManon LaunayAudrey DerobertmasureSandrine Lefeuvre, Eric DannaouiEliane M. Billaud. (2022) Antifungal Drugs TDM: Trends and Update. Therapeutic Drug Monitoring 44:1, pages 166-197.
Crossref
Roger J Brüggemann, Rebecca Verheggen, Emmy Boerrigter, Marta Stanzani, Paul E Verweij, Nicole M A Blijlevens & Russell E Lewis. (2022) Management of drug–drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. The Lancet Haematology 9:1, pages e58-e72.
Crossref
Mengfei Cheng, Fang Yang, Jiahui Liu, Dan Yang, Shuo Zhang, Yang Yu, Shuai Jiang & Mei Dong. (2021) Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies. Frontiers in Cardiovascular Medicine 8.
Crossref
Eric D. Eisenmann, Qiang Fu, Elizabeth M. Muhowski, Yan Jin, Muhammad Erfan Uddin, Dominique A. Garrison, Robert H. Weber, Jennifer A. Woyach, John C. Byrd, Alex Sparreboom & Sharyn D. Baker. (2021) Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition. Cancer Research Communications 1:2, pages 79-89.
Crossref
Binwei Lin, Huan Du, Jinjia Fan, Dan Huang, Feng Gao, Jie Li, Yu Zhang, Gang Feng, Tangzhi Dai & Xiaobo Du. (2021) Radioimmunotherapy Combined With Low-Intensity Ultrasound and Microbubbles: A Potential Novel Strategy for Treatment of Solid Tumors. Frontiers in Oncology 11.
Crossref
Wei Xu, Shenmiao Yang, Keshu Zhou, Ling Pan, Zengjun Li, Jianfeng Zhou, Sujun Gao, Daobin Zhou, Jianda Hu, Ru Feng, Haiwen Huang, Meng Ji, Haiyi Guo, Jane Huang, William Novotny, Shibao Feng & Jianyong Li. (2020) Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. Journal of Hematology & Oncology 13:1.
Crossref
Camille Hardy-Abeloos, Rachel Pinotti & Janice Gabrilove. (2020) Ibrutinib dose modifications in the management of CLL. Journal of Hematology & Oncology 13:1.
Crossref
Alejandro Cabrera-Andrade, Andrés López-Cortés, Gabriela Jaramillo-Koupermann, Humberto González-Díaz, Alejandro Pazos, Cristian R. Munteanu, Yunierkis Pérez-Castillo & Eduardo Tejera. (2020) A Multi-Objective Approach for Anti-Osteosarcoma Cancer Agents Discovery through Drug Repurposing. Pharmaceuticals 13:11, pages 409.
Crossref
Constantine S. TamHang Quach, Andrew NicolXavier BadouxHannah RoseH. Miles Prince, Michael F. LeahyRichard Eek, Nicholas WickhamSushrut S. PatilJane Huang, Radha Prathikanti, Aileen Cohen, Rebecca Elstrom, William Reed, Jingjing Schneider & Ian W. Flinn. (2020) Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. Blood Advances 4:19, pages 4802-4811.
Crossref
Jan Jong, Anna Mitselos, Wojciech Jurczak, Raul Cordoba, Carlos Panizo, Tomasz Wrobel, Monika Dlugosz‐Danecka, James Jiao, Juthamas Sukbuntherng, Daniele Ouellet & Peter Hellemans. (2020) Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6. Pharmacology Research & Perspectives 8:5.
Crossref
Yuqin Song, Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Haiyi Guo, Lei Zhou, Rebecca Elstrom, Jane Huang, William Novotny, Rachel Wei & Jun Zhu. (2020) Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. Clinical Cancer Research 26:16, pages 4216-4224.
Crossref
Chelsea Gustafson, Molly Koslosky, Jill Leslie & Christopher Walczak. (2020) Antifungal and Oral Anticancer Therapy Drug Interactions. Current Fungal Infection Reports 14:2, pages 130-140.
Crossref
Tuija Tapaninen, Aleksi M. Olkkola, Aleksi Tornio, Mikko Neuvonen, Erkki Elonen, Pertti J. Neuvonen, Mikko Niemi & Janne T. Backman. (2019) Itraconazole Increases Ibrutinib Exposure 10‐Fold and Reduces Interindividual Variation—A Potentially Beneficial Drug‐Drug Interaction. Clinical and Translational Science 13:2, pages 345-351.
Crossref
Rossana Maffei, Monica Maccaferri, Laura Arletti, Stefania Fiorcari, Stefania Benatti, Leonardo Potenza, Mario Luppi & Roberto Marasca. (2020) Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections. Blood Reviews 40, pages 100635.
Crossref
Takeo Yasu, Kenji Momo, Seiichirou Kuroda & Toyotaka Kawamata. (2020) Fluconazole Increases Ibrutinib Concentration. American Journal of Therapeutics 27:6, pages e620-e621.
Crossref
Nikki Blosser, Jennifer Jupp, Patrick Yau & Douglas Stewart. (2019) Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma. Clinical Pharmacokinetics 59:1, pages 7-23.
Crossref
Jiangnan Dong, Su Li & Guangxuan Liu. (2019) In vitro metabolism of ibrutinib in rat, dog and human hepatocytes using liquid chromatography combined with diode‐array detection and Q‐Exactive Orbitrap tandem mass spectrometry . Rapid Communications in Mass Spectrometry 33:23, pages 1804-1815.
Crossref
Georgios Chamilos, Michail S Lionakis & Dimitrios P Kontoyiannis. (2018) Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. Clinical Infectious Diseases 66:1, pages 140-148.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.